Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
IL110464A0 - Novel proteins for the diagnosis, imaging, and therapy of human cancer - Google Patents
[go: Go Back, main page]

IL110464A0 - Novel proteins for the diagnosis, imaging, and therapy of human cancer - Google Patents

Novel proteins for the diagnosis, imaging, and therapy of human cancer

Info

Publication number
IL110464A0
IL110464A0 IL11046494A IL11046494A IL110464A0 IL 110464 A0 IL110464 A0 IL 110464A0 IL 11046494 A IL11046494 A IL 11046494A IL 11046494 A IL11046494 A IL 11046494A IL 110464 A0 IL110464 A0 IL 110464A0
Authority
IL
Israel
Prior art keywords
diagnosis
therapy
imaging
human cancer
novel proteins
Prior art date
Application number
IL11046494A
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Priority to IL11046494A priority Critical patent/IL110464A0/en
Publication of IL110464A0 publication Critical patent/IL110464A0/en
Priority to PCT/IB1995/000627 priority patent/WO1996003502A2/en
Priority to AU29906/95A priority patent/AU2990695A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727Mucins, e.g. human intestinal mucin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11046494A 1994-07-26 1994-07-26 Novel proteins for the diagnosis, imaging, and therapy of human cancer IL110464A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL11046494A IL110464A0 (en) 1994-07-26 1994-07-26 Novel proteins for the diagnosis, imaging, and therapy of human cancer
PCT/IB1995/000627 WO1996003502A2 (en) 1994-07-26 1995-07-21 Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer
AU29906/95A AU2990695A (en) 1994-07-26 1995-07-21 Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11046494A IL110464A0 (en) 1994-07-26 1994-07-26 Novel proteins for the diagnosis, imaging, and therapy of human cancer

Publications (1)

Publication Number Publication Date
IL110464A0 true IL110464A0 (en) 1994-10-21

Family

ID=11066387

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11046494A IL110464A0 (en) 1994-07-26 1994-07-26 Novel proteins for the diagnosis, imaging, and therapy of human cancer

Country Status (3)

Country Link
AU (1) AU2990695A (en)
IL (1) IL110464A0 (en)
WO (1) WO1996003502A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19917195B4 (en) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptide for triggering an immune reaction against tumor cells, pharmaceutical compositions containing them, their uses, nucleic acid coding therefor and expression vector containing said nucleic acid
CA2383737C (en) 1999-09-08 2011-01-18 Transgene S.A. Muc-1 derived peptides
JP2003533181A (en) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート Mucin-1 derived antigen and its use in immunotherapy
EP2241887B1 (en) 2000-11-27 2015-01-14 Minerva Biotechnologies Corporation Diagnostics, drug screening and treatment for cancer
EP1531842A4 (en) * 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc REGULATION OF CELL PROLIFERATION BY MUC1
JP2005508839A (en) 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド Antibodies against peptides and MUC1 protein
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
JP2004536578A (en) * 2001-03-30 2004-12-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Anti-MUC-1 single chain antibodies for tumor targeting
EP1451332B1 (en) * 2001-11-27 2008-02-13 neXyte AB Production of eukaryotic proteins and nucleic acid molecules in c. elegans
WO2003089451A2 (en) * 2002-04-22 2003-10-30 Dyax Corporation Antibodies specific for mucin polypeptide
CA2491017A1 (en) * 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
GB2395270B (en) 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
CA2537263C (en) * 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
WO2006081553A2 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. ANTI-MUC1 α/ß ANTIBODIES
EP1910840A2 (en) * 2005-05-26 2008-04-16 Dana-Farber Cancer Institute, Inc. Modulation of muc1-dependent anti-estrogen resistance
SI1889059T1 (en) 2005-05-27 2009-12-31 Oncimmune Ltd Improved immunological procedures
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
CN101632020B (en) 2006-09-13 2013-11-27 昂西免疫有限公司 Improved immunoassay method
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
CN116199790A (en) 2015-02-10 2023-06-02 米纳瓦生物技术公司 Humanized anti-MUCl antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929097D0 (en) * 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides

Also Published As

Publication number Publication date
AU2990695A (en) 1996-02-22
WO1996003502A2 (en) 1996-02-08
WO1996003502A3 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
IL110464A0 (en) Novel proteins for the diagnosis, imaging, and therapy of human cancer
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
HUP9801390A3 (en) Radiolabeled peptides for diagnosis and therapy
IL116847A0 (en) Diagnostic imaging contrast agents and methods for extending the blood retention thereof
ZA99693B (en) Compounds for therapy and diagnosis of lung cancer and methods for their use.
IL121426A (en) Spectral bio-imaging methods for biological research medical diagnostics and therapy
AU4473596A (en) Methods of human prostate cancer diagnosis
ZA982968B (en) Compositions and methods for the treatment and diagnosis of breast cancer
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
GB2293651B (en) Medical untrasound imaging
AU1214995A (en) Cdna probe for breast cancer diagnosis and treatment
GB9811598D0 (en) Diagnosis and treatment of cancer
AU4953693A (en) Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
AU6288698A (en) Apparatus for stimulating the human body
GB9408084D0 (en) Medical treatment
GB9421223D0 (en) Tissue imaging in gene therapy
ZA976547B (en) Lipid-binding proteins and their therapeutic and diagnostic use
IL136210A0 (en) Reagent for tumor therapy and/or imaging
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
GB9716787D0 (en) Materials and methods for the diagnosis and treatment of breast cancer
EP0561297A3 (en) Tissue antigen and diagnostic method for human osteoporosis using the same
AU5135498A (en) Immunoconjugates comprising human monoclonal antibodies or fragments thereof for diagnostic and therapy
SI1157041T1 (en) Antibodies for cancer therapy and diagnosis
AU4499196A (en) Antibodies for use in cancer therapy and diagnosis